iTeos Therapeutics signs US$2.75 B Agreement with GlaxoSmithKline

By Ashish Tripathi

Pharma Deals Review: Vol 2021 Issue 7 (Table of Contents)

Published: 28 Jul-2021

DOI: 10.3833/pdr.v2021.i7.2629     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its oncology pipeline, GlaxoSmithKline (GSK) has entered into a collaboration agreement with iTeos Therapeutics to develop and commercialise the latter’s monoclonal antibody, EOS-448, for the treatment of advanced solid tumours...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details